PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) (a) Full name of ...

Q4 2024 Earnings Call Transcript September 19, 2024 iPower Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $0.015. Operator: Good afternoon, everyone, and thank you for ...

On September 17, 2024, BioCardia received notice from Nasdaq confirming that the Company has demonstrated compliance with Listing Rule 5550 (b) (1) (the “Equity Rule”) of The Nasdaq Stock Market.

Q4 2024 Earnings Call Transcript September 12, 2024 Farmer Bros. Co. misses on earnings expectations. Reported EPS is ...

Q2 2025 Earnings Call Transcript September 11, 2024 Vera Bradley, Inc. misses on earnings expectations. Reported EPS is $0.13 ...

Crunchfish AB ("Crunchfish" or the "Company"), listed on Nasdaq First North Growth Market ("Nasdaq First North"), has today, September 20, 2024, subject to a subsequent approval by the Extraordinary G ...

JOHANNESBURG, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the fourth quarter (“Q4 2024”) and year ended June 30, 2024 (“FY 2024”).

NBT Bancorp Inc. (“NBT”) (NASDAQ: NBTB) and Evans Bancorp, Inc. (“Evans”) (NYSE American: EVBN) today announced they have entered into a definitive agreement pursuant to which Evans will merge with ...

This Letter has no immediate effect on the listing of the Company's securities on Nasdaq. As previously disclosed in the Notification of Late Filing on Form 12b-25 filed on March 18, 2024 ...

New Nano-Grid System ‘SOLIS’ and ‘COR‘ Stores 4,000Wh or more of Clean Energy Daily, Offering Modular, Portable Power ...

2024 (the "Q2 Form 10-Q"), with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c ...

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with ...